UNSPSC 51372326: Piminodine esylate

This classification denotes an opioid receptor agonist with the molecular formula C23H30N2O2.C2H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2C29WCQ951, chemically known as 4-piperidinecarboxylic acid, 4-phenyl-1-(3-(phenylamino)propyl)-, ethyl ester but more generally known as piminodine esylate, which bears US NIH Compound Identifier 21950. Most nations, for tariff and trade purposes, schedule piminodine esylate under HS 29333999 and SITC 51574.

As of Q4 2014, PIMINODINE ESYLATE remains US FDA's Preferred Term for this commodity. Piminodine esylate bears US NLM identifiers UMLS ID C1321936 and NCI Concept Code C80987. SMILES: CCOC(=O)C1(CCN(CC1)CCCNC2CCCCC2)C3CCCCC3.CCS(=O)(=O)O.

UNSPSC 51372326 Piminodine esylate is a Commodity code that captures individual pharmaceutical products, but recent state and local procurement activity under this code shows minimal direct alignment with the specific active pharmaceutical ingredient. Instead, issuing bodies are acquiring pharmaceutical products through broader cooperative purchasing agreements and health-initiative procurement vehicles that encompass multiple drugs and therapeutic categories. Seminole County, Florida is conducting an IFB for naloxone and drug deactivation systems for community health support, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting RFP responses from manufacturers to supply generic pharmaceuticals and over-the-counter products through authorized wholesalers to participating state and local government entities across multiple jurisdictions including Oregon. These opportunities reflect state and local procurement of pharmaceuticals as consumable health-program inputs rather than as named-ingredient line items, suggesting that the code's nominal scope diverges from current buying patterns in the market.

Geographic activity centers on Florida and a multi-state cooperative purchasing footprint anchored by Minnesota. Seminole County's IFB for naloxone and drug deactivation systems (Solicitation IFB60459723LAS, due July 26, 2023) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with one-year renewal option and potential FEMA funding. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802, due March 26, 2026) establishes cooperative purchasing for participating states and localities, requiring manufacturer pricing for specific NDC-coded products through three authorized wholesalers with products effective July 1, 2026; evaluation emphasizes price competitiveness (75 percent) and administrative compliance. The Texas Health and Human Services Commission issued a preliminary RFI (HHS0017013, posted April 3, 2026) to gather vendor intelligence on direct-to-manufacturer prescription programs for the Therapeutic Pharmacy Initiative, signaling future procurement strategy development rather than immediate award activity. The code shows sparse direct relevance to piminodine esylate procurement specifically.